Compare XL Axiata Tbk. (EXCL) vs Tempo Scan Pacific Tbk. (TSPC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
XL Axiata Tbk. vs Tempo Scan Pacific Tbk. — how do they compare? XL Axiata Tbk. trades at Rp2,630 (market cap 46.59T, 13.35M 24h volume), while Tempo Scan Pacific Tbk. trades at Rp2,780 (market cap 12.58T, 235.2K 24h volume). The key difference: XL Axiata Tbk. is far larger — about 3.7× Tempo Scan Pacific Tbk.'s market cap, and XL Axiata Tbk. is more actively traded (13.35M versus 235.2K). Which is the better fit depends on your goals.
| EXCL | TSPC | |
|---|---|---|
Market Cap | 46.59T | 12.58T |
Volume | 13.35M | 235.2K |
Lot | 133.5K | 2.35K |
Turnover | 34.79B | 649.94M |
Average Price | 2,605.7 | 2,763.37 |
Value | 34.79B | 649.94M |
Indicative Equilibrium Price | 2,630 | 2,780 |
Indicative Equilibrium Volume | 4.96K | 9 |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About XL Axiata Tbk.
PT XL Axiata Tbk (the Company) which was previously known as PT Excelcomindo Pratama Tbk, was initially established under the name PT Grahametropolitan Lestari. The Company was established on Oct 6th, 1989.The articles of association have been amended several times, most recently on Aug 2, 2005, concerning among other the change of par value, equity and public offering. The company started its operation since October 1996 and was the 3rd biggest company in Indonesia for the number of customer and income.
Read more on EXCL →About Tempo Scan Pacific Tbk.
PT. Tempo Scan Pacific Tbk (the Company) was established in the Republic of Indonesia dated 20 May 1970, under its original name PT Scanchemie within the framework of the Domestic Capital Investment Law No. 6 year 1968, as amended by Law No. 12 year 1970, based on Notarial Deed No. 37 of Ridwan Suselo, S.H. The company is famous for such pharmaceutical products as Bodrex, Hemaviton and Neo-Rheumacyl.
Read more on TSPC →
